Author/Authors :
Behnava، Bita نويسنده Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for Gastroenterology and Liver diseases, Tehran, IR Iran , , Sharafi، Heidar نويسنده Molecular Division, Iran Hepatitis Network, Tehran, IR Iran , , Keshvari، Maryam نويسنده Iranian Blood Transfusion Organization research Center, Tehran, IR Iran , , Pouryasin، Ali نويسنده Armin Pathobiology Laboratory, Tehran, IR Iran , , Mehrnoush، Leila نويسنده Middle East Liver Disease Center, Tehran, IR Iran , , Salimi، Shima نويسنده Middle East Liver Disease Center, Tehran, IR Iran , , Karimi Elizee، Pegah نويسنده Tehran Hepatitis Center, Tehran , , Ghazimoghaddam، Mehran نويسنده Armin Pathobiology Laboratory, Tehran, IR Iran , , Alavian، Seyed-Moayed نويسنده ,
Abstract :
Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic patients. In these patients, iron overload and their comorbidities make difficulties during Pegylated-Interferon (PEG-IFN) and Ribavirin (RBV) therapy. We aimed to assess the impact of polymorphisms near the IL28B gene on virological response in HCV - infected thalassemic patients, who were treated with PEG-IFN and RBV. This cross - sectional study was conducted on 143 thalassemic patients with chronic hepatitis C, who were treated with a combination of PEG-IFN and RBV regimen. The rs12979860 and rs8099917 polymorphisms were assessed as the most common polymorphisms near the IL28B gene by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The rate of sustained virological response (SVR) was significantly lower in thalassemic patients with HCV genotype-1 infection compared to patients with HCV genotype-3 infection. Among baseline predictors, rs12979860 and rs8099917 polymorphisms were found to be the only parameters associated with achievement of SVR in thalassemic patients with HCV genotype-1 infection however, there was no association between these polymorphisms and the rate of SVR in thalassemic patients with HCV genotype-3 infection. In HCV genotype-1- infected thalassemic patients with rs12979860 CC genotype and without severe comorbidities, PEG-IFN and RBV combination therapy can be tried yet in those with rs12979860 CT/TT it may be reasonable to treat cases with new direct-acting antivirals.
